title: Radical radiation therapy for prostate cancer in Japan: a Patterns of Care Study report.
abstract: BACKGROUND
  The patterns of radical radiation therapy for prostate cancer are unclear in Japan. A Patterns of Care Study was performed throughout Japan to examine the patterns of radiation therapy for prostate cancer.
  
  
  METHODS
  From 1999 to 2000, extramural audits were performed on 50 randomly selected institutions (approximately 7% of all institutions in Japan). Detailed information was collected on a total of 311 prostate cancer patients without evidence of distant metastases, who were treated by radiation therapy between 1996 and 1998. Of these 311 patients, 162 treated radically using photon beams were analyzed in this study.
  
  
  RESULTS
  Eighty percent of the patients had high-risk diseases defined as T3 or T4 tumors, a pretreatment prostate-specific antigen level >20 ng/ml or poorly differentiated adenocarcinoma. Androgen ablation was performed in 85.8% of patients and the median duration of hormonal therapy before and after radiation therapy was 5.3 and 21.4 months, respectively. The median total dose of radiation therapy to the prostate was 65.0 Gy (range: 20-74 Gy). The 3-year overall and biochemical relapse-free survival rates were 86.7 and 86.1%, respectively. Late toxicity was mild, with only nine patients (5.6%) exhibiting grade 2 late morbidity.
  
  
  CONCLUSIONS
  The majority of the patients who received radical radiation therapy in Japan have high-risk disease. Androgen ablation plus radiation therapy was commonly used to treat these patients and resulted in high rates of initial control with a low risk of complications.
authors.affiliation: Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan. nakam@radiol.med.kyushu-u.ac.jp
authors.forename: Katsumasa
authors.initials: K
authors.lastname: Nakamura
authors.forename: Teruki
authors.initials: T
authors.lastname: Teshima
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Imai
authors.forename: Masahiko
authors.initials: M
authors.lastname: Koizumi
authors.forename: Norio
authors.initials: N
authors.lastname: Mitsuhashi
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Inoue
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008485:Medical Audit; D008875:Middle Aged; D010818:Practice Patterns, Physicians'; D011364:Professional Practice; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D020266:Radiotherapy, Conformal; D011882:Radiotherapy, High-Energy; D015996:Survival Rate
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen